SCHEMBL15344142

SCHEMBL15344142

CCN1C(c2ccccc2)N2C(c3ccccc3)N2C1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RECQL P46063 1/20 0.39
LMNA P02545 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 1/20 0.37
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
DRD2 P14416 1/20 0.35
PRCP P42785 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
ABCB1 P08183 1/20 0.33
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15340880 0.75 RECQL (0.43) RECQLTSHRKMT2APOLBALDH1A1
SCHEMBL3457600 0.71 ATM (0.40) ATMSMN1; SMN2NPSR1RECQLLMNA
SCHEMBL15461422 0.70 PRCP (0.50) RECQLLMNAADORA3MEN1TSHR
SCHEMBL17153987 0.69 ATM (0.39) ATMSMN1; SMN2NPSR1RECQLLMNA
SCHEMBL3778884 0.65 GAA (0.37) ATMSMN1; SMN2NPSR1RECQLLMNA
SCHEMBL5291704 0.64 DRD2 (0.42) ATMSMN1; SMN2NPSR1RECQLLMNA
SCHEMBL11456622 0.64 ATM (0.46) ATMSMN1; SMN2NPSR1LMNADRD2
SCHEMBL8045783 0.64 SLC18A3 (0.58) MEN1KMT2ADRD2
SCHEMBL5299435 0.64 DRD2 (0.46) RECQLMEN1TSHRHTTKMT2A
SCHEMBL18691187 0.64 ALDH1A1 (0.43) SMN1; SMN2NPSR1RECQLMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281389-A1 NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281389-A1 NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA XPO1, XPOT, DDB1 ATM 1762/4885SMN1; SMN2 2173/4885NPSR1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.